Show simple item record

Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes

dc.contributor.authorSchwaab, J
dc.contributor.authorNaumann, N
dc.contributor.authorLuebke, J
dc.contributor.authorJawhar, M
dc.contributor.authorSomervaille, Tim CP
dc.contributor.authorWilliams, Mark S
dc.contributor.authorFrewin, R
dc.contributor.authorJost, PJ
dc.contributor.authorLichtenegger, FS
dc.contributor.authorLa Rosee, P
dc.contributor.authorStorch, N
dc.contributor.authorHaferlach, T
dc.contributor.authorHorny, HP
dc.contributor.authorFabarius, A
dc.contributor.authorHaferlach, C
dc.contributor.authorBurchert, A
dc.contributor.authorHofmann, WK
dc.contributor.authorCross, NCP
dc.contributor.authorHochhaus, A
dc.contributor.authorReiter, A
dc.contributor.authorMetzgeroth, G
dc.date.accessioned2020-06-15T12:57:42Z
dc.date.available2020-06-15T12:57:42Z
dc.date.issued2020en
dc.identifier.citationSchwaab J, Naumann N, Luebke J, Jawhar M, Somervaille TCP, Williams MS, et al. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol. 2020.en
dc.identifier.pmid32279331en
dc.identifier.doi10.1002/ajh.25825en
dc.identifier.urihttp://hdl.handle.net/10541/622993
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/ 10.1002/ajh.25825en
dc.titleResponse to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genesen
dc.typeArticleen
dc.contributor.departmentDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.en
dc.identifier.journalAmerican Journal of Hematologyen
dc.description.noteen]
refterms.dateFOA2020-06-22T12:46:38Z


Files in this item

Thumbnail
Name:
ajh.pdf
Size:
1.787Mb
Format:
PDF
Description:
From UNPAYWALL
Download

This item appears in the following Collection(s)

Show simple item record